NASDAQ: TSHA
Taysha Gene Therapies Inc Stock Ownership - Who owns Taysha Gene Therapies?

Insider buying vs selling

Have Taysha Gene Therapies Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Paul B. Manning10% Owner2025-05-30750,000$2.75
$2.06MBuy
Kamran AlamCHIEF FINANCIAL OFFICER2025-03-1129,843$1.69
$50.43kSell

1 of 1

TSHA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TSHA insiders and whales buy or sell their stock.

TSHA Shareholders

What type of owners hold Taysha Gene Therapies Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Avoro Capital Advisors LLC9.32%19,999,999$46.80MInstitution
Rtw Investments LP8.75%18,787,866$43.96MInstitution
Morgan Stanley7.85%16,846,374$39.42MInstitution
Fmr LLC7.28%15,631,954$36.58MInstitution
Blackrock Inc6.33%13,589,178$31.80MInstitution
Ra Capital Management LP5.06%10,872,503$25.44MInstitution
Octagon Capital Advisors LP4.98%10,700,000$25.04MInstitution
Ra Session Ii4.20%9,012,837$21.09MInsider
Vanguard Group Inc4.09%8,770,921$20.52MInstitution
Audentes Therapeutics Inc3.39%7,266,342$17.00MInsider

1 of 3

TSHA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TSHA77.69%14.30%Net BuyingNet Buying
BCYC58.23%41.77%Net BuyingNet Selling
ATAI10.93%36.61%Net Buying
TYRA60.78%39.22%Net BuyingNet Buying
CELC81.60%12.34%Net Selling

Taysha Gene Therapies Stock Ownership FAQ

Who owns Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ: TSHA) is owned by 77.69% institutional shareholders, 14.30% Taysha Gene Therapies insiders, and 8.02% retail investors. Ra Session Ii is the largest individual Taysha Gene Therapies shareholder, owning 9.01M shares representing 4.20% of the company. Ra Session Ii's Taysha Gene Therapies shares are currently valued at $21.81M.

If you're new to stock investing, here's how to buy Taysha Gene Therapies stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.